+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Growth Hormone Deficiency Market Size was valued at USD 3.5 Billion in 2022. The Growth Hormone Deficiency market Distribution Channel is projected to grow from USD 3.7 Billion in 2023 to USD 6.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.30% during the forecast period (2023 - 2032). An increase in cases of pituitary malfunction, the creation of recombinant human growth hormone therapies, and a rise in the use of human growth hormones outside of recommended dosages, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Somatotropin, another name for human growth hormone (HGH), is a peptide hormone that is essential for human development because it stimulates cell growth, division, and regeneration in humans. Insufficient hGH synthesis by the pituitary gland results in growth hormone (GH) insufficiency in humans. Recombinant human growth hormone is injected subcutaneously to address this human deficit. Humans may also experience growth hormone insufficiency due to a number of genetic illnesses, such as Prader-Willi syndrome and Turner syndrome, which can delay puberty and result in shorter-than-average height. Growth hormone insufficiency in humans is a rare illness that affects less than one in 3,000 to one in 10,000 children in the U.S., according to data from the American Academy of Paediatrics. Currently, hGH is frequently misused by bodybuilders, sportsmen, and older adults as an anti-aging medication and as a performance-enhancing anabolic substance.
The market for human growth hormones is anticipated to be driven primarily by a strong product pipeline and considerable R&D initiatives for the development of innovative growth hormone therapies. For instance, Novo Nordisk reported Phase II clinical trial data of Somapacitan, an experimental GH medication recommended for the treatment of paediatric growth hormone insufficiency, in September 2018. Additionally, Ascendis Pharma A/S released their TransCon hGH Phase III clinical trial findings in May 2019. This product is intended to treat paediatric growth hormone insufficiency. Similar to this, a number of important firms, such as Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences, are engaged in R&D operations for the creation of innovative HGH medicines.
Additionally, the market is anticipated to be driven by campaigns launched by numerous public and private organisations to raise awareness of GH deficiencies and treatments for human growth hormone. International Children's Growth Awareness Day is observed annually by the International Coalition of Organisations Supporting Endocrine Patients (ICOSEP), a nonprofit organisation based in the United States, to raise awareness of the importance of early detection and treatment of growth hormone disorders in people, particularly children.
Additionally, several businesses are investing in research and development to produce a growth hormone that has less adverse effects and will be used as a long-term therapy. The rise in conditions brought on by this hormone's deficit can be linked to the market's expansion. Governments and other commercial organisations make ongoing efforts to increase public knowledge of growth hormone deficiency and high productivity. Additional factors including improved treatment awareness and an increase in the prevalence of multiple health issues, including neuropsychiatric diseases, will boost demand for human growth hormone medications and encourage market expansion. The market for human growth hormones is expected to expand due to the speedy development of novel compounds. Thus, driving the Growth Hormone Deficiency market revenue.
The global Growth Hormone Deficiency market segmentation, based on Brand, includes Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope. Norditropin segment dominated the global market in 2022. It has maintained that position for years, and the evaluation period suggests that growth will continue at a rapid pace. Norditropin HGH is one of Novo Nordisk's most popular prefilled and premixed products of human growth hormone.
The global Growth Hormone Deficiency market segmentation, based on Application, includes Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small For Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, and Prader Willi Syndrome. Pediatric Growth Hormone Deficiency segment dominated the global Growth Hormone Deficiency market in 2022. This is attributable to increased public awareness of paediatric growth hormone insufficiency early detection and therapy as well as the launch of new drugs. For instance, Ascendis Pharma A/S received Orphan Designation from the European Commission (EC) for TransCon hGH in October 2018. It is advised to treat paediatric GH deficiency with this human investigational long-acting GH drug.
The global Growth Hormone Deficiency market segmentation, based on Route of Administration, includes Subcutaneous, Intramuscular, and Intravenous. Subcutaneous segment dominated the global Growth Hormone Deficiency market in 2022. This is because the hormone, after being supplied subcutaneously, absorbs well in cells, which is advantageous for the patients.
The global Growth Hormone Deficiency market segmentation, based on Distribution Channel, includes Hospital Pharmacies, Retail Pharmacies, Clinics, and E-commerce. Hospital Pharmacies segment dominated the global market in 2022. Because more people are aware of GH insufficiency in humans and how to treat it, there has been an increase in hospital visits, which is thought to be the cause of this high percentage.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Growth Hormone Deficiency Market dominated this market in 2022 (45.80%). This is due to elements like a favourable reimbursement environment, a developed healthcare infrastructure, considerable government initiatives, and rising public awareness of healthcare issues. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several major companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human GH medicines in the area. Further, the U.S. Growth Hormone Deficiency market held the largest market share, and the Canada Growth Hormone Deficiency market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Europe Growth Hormone Deficiency market accounted for the healthy market share in 2022. The European market benefits from increased access to cutting-edge pharmaceuticals as a result of the presence of significant companies in the area. Further, the German Growth Hormone Deficiency market held the largest market share, and the U.K Growth Hormone Deficiency market was the fastest growing market in the European region.
The Asia Pacific Growth Hormone Deficiency market is expected to register significant growth from 2023 to 2032. By obtaining clearance and launching innovative products, large market share in potential Asia Pacific nations like China and Japan is a goal for major firms. For instance, the phase III clinical trial of the pharmaceutical company Novo Nordisk A/S's HGH somapacitan, which is indicated for the treatment of adult growth hormone insufficiency, was started in Japan in March 2017. Moreover, China’s Growth Hormone Deficiency market held the largest market share, and the Indian Growth Hormone Deficiency market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Growth Hormone Deficiency market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Growth Hormone Deficiency Industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Growth Hormone Deficiency Industry to benefit clients and increase the market sector. In recent years, the Growth Hormone Deficiency Industry has offered some of the most significant advantages to medicine. Major players in the Growth Hormone Deficiency market, including Anhui Anke Biotechnology (Group) Co. Ltd., Pfizer Inc., Genetech Inc., Biopartners GmbH, Lifetech Labs, Zhongshan Hygene Biopharm Co. Ltd., Novo Nordisk A/S, Eli Lily and Company, and Ipsen S.A., are attempting to increase market demand by investing in research and development operations.
A division of Novo Holdings AS, Novo Nordisk AS (Novo Nordisk) is a healthcare organisation dedicated to the discovery, development, and production of cutting-edge biological therapies. It focuses on developing medications to treat diabetes and other severe chronic ailments, such as haemophilia, problems of the human growth hormone (HGH), uncommon blood and endocrine diseases, and obesity. Pre-filled insulin delivery systems, glucagon hypokit, cartridges, needles, vials, estradiol for hormone replacement, recombinant pharmaceuticals for haemophilia, glucagon, and oral diabetes medications are all part of the company's portfolio. The corporation uses subsidiaries across North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia to market its products. The headquarters of Novo Nordisk are in Bagsvaerd, Denmark. An agreement was signed between Novo Nordisk and Strongbridge Biopharma in October 2018 to purchase the rights to MACRILEN in the United States and Canada. The FDA has approved only one oral medication, MACRILEN (macimorelin), for use in diagnosing adult growth hormone insufficiency.
Biopharmaceuticals are discovered, developed, produced, and sold by Pfizer Inc. The business sells goods to cure a range of ailments, including cancer, inflammation, rare diseases, metabolic, cardiovascular, and metabolic and pain disorders, as well as women's health issues. Additionally, it offers contract manufacturing services, sterile injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and medicines. Pfizer offers its goods through distributors, merchants, pharmacies, hospitals, private physician offices, clinics, and public institutions. India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US are all home to significant manufacturing facilities for it. The company ships its goods to Europe, Africa, the Middle East, Asia-Pacific, Australia, and North and South America. In the US, New York serves as the home of Pfizer. According to a February 2021 press release from The Pfizer and OPKO Health Inc., the European Medicines Agency has approved Somatrogon for the treatment of people who do not produce enough juvenile growth hormone.
· Anhui Anke Biotechnology (Group) Co. Ltd.
· Pfizer Inc.
· Genetech Inc.
· Biopartners GmbH
· Lifetech Labs
· Zhongshan Hygene Biopharm Co. Ltd.
· Novo Nordisk A/S
· Eli Lily and Company
· Ipsen S.A.
August 2021: In August 2021, the FDA approved the injectable SKYTROFA from Ascendis Pharma. The corporation will be able to make a sizable profit when this product is launched on the world market.
· Norditropin
· Genotropin
· Humatrope
· Saizen
· Omnitrope
· Pediatric Growth Hormone Deficiency
· Idiopathic Short Stature
· Small For Gestational Age
· Turner Syndrome
· Adult Growth Hormone Deficiency
· Prader Willi Syndrome
· Subcutaneous
· Intramuscular
· Intravenous
· Hospital Pharmacies
· Retail Pharmacies
· Clinics
· E-commerce
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
Report Scope
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 3.5 Billion |
|
Market Size 2023 |
USD 3.7 Billion |
|
Market Size 2032 |
USD 6.2 Billion |
|
Compound Annual Growth Rate (CAGR) |
6.30% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Brand, Application, Route of Administration, Distribution Channel, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Anhui Anke Biotechnology (Group) Co. Ltd., Pfizer Inc., Genetech Inc., Biopartners GmbH, Lifetech Labs, Zhongshan Hygene Biopharm Co. Ltd., Novo Nordisk A/S, Eli Lily and Company, and Ipsen S.A. |
|
Key Market Opportunities |
Increasing elderly population |
|
Key Market Dynamics |
The development of recombinant human growth hormone medications, an increase in cases of pituitary dysfunction, and an increase in the use of human growth hormones outside of prescribed dosages |
The global Growth Hormone Deficiency Market was valued at USD 3.5 billion in 2022, and it is estimated to reach USD 6.2 billion by 2032.
The global market is projected to grow at a CAGR of 6.30% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Anhui Anke Biotechnology (Group) Co. Ltd., Pfizer Inc., Genetech Inc., Biopartners GmbH, Lifetech Labs, Zhongshan Hygene Biopharm Co. Ltd., Novo Nordisk A/S, Eli Lily and Company, and Ipsen S.A.
The Norditropin Brand dominated the market in 2022
The Pediatric Growth Hormone Deficiency Application had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL6543
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst